Mexico COFEPRIS Equivalence Pathway: New Guidance for Medical Device Registration

Mexico's COFEPRIS released new guidance in late July 2026 clarifying documentation requirements for its Equivalence and Abbreviated regulatory pathways. This episode provides a practical breakdown of the key changes affecting medical device and IVD manufacturers. We discuss the updated specifications for critical documents like the Certificate of Free Sale and Letter of Equivalence, who is impacted by these immediate changes, and actionable steps your regulatory team can take to ensure your submission dossiers are compliant and can avoid unnecessary delays. Key Questions: - What are the COFEPRIS Equivalence and Abbreviated pathways for medical device registration? - What specific documentation requirements were clarified in the new July 2026 guidance? - How does this guidance affect manufacturers with existing FDA, Health Canada, or EU approvals? - Are there new requirements for the Certificate of Free Sale or technical summaries in Mexico? - What is the deadline for complying with these new clarifications? - How can regulatory teams proactively update their submission dossiers for Mexico? - What role does the Mexico Registration Holder play in navigating these changes? - What are the most common pitfalls to avoid when using the equivalence route in Mexico? Sources: - https://www.medenvoy.com/resources/news/cofepris-publishes-new-guidance-on-medical-device-registration-via-equivalence-and-abbreviated-pathways - https://www.pure-global.com/insights/glossary/cofepris-mexico-medical-device-regulations/ - https://www.medicaldevice-network.com/comment/cofepris-launches-new-framework-for-medical-device-registration/ How Pure Global can help: Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies seeking to enter or maintain their presence in the Mexican market. Our local experts in Mexico can act as your official Registration Holder (MRH), manage the entire COFEPRIS submission process, and ensure your technical dossier aligns with the latest guidance, including the Equivalence Pathway requirements. We leverage advanced AI tools to streamline document compilation and ensure accuracy, helping you achieve faster, more predictable market access. Contact us at [email protected], visit https://pureglobal.com, or explore our free regulatory AI tools and device database at https://pureglobal.ai.